Tata Medical and Diagnostics Revenue and Competitors

Tata Medical and Diagnostics (Tata MD) aims to provide leading-edge, patient-centric solutions, with a clear vision to make healthcare accessible and reliable. Tata Medical and Diagnostics Ltd (Tata MD) is a new healthcare venture from the Tata group, India’s largest business conglomerate. Tata MD aims to provide leading-edge, patient-centric solutions, with a clear vision to make healthcare access more accessible and reliable. Tata MD’s products and solutions will span different facets of a fast-evolving healthcare economy including the launch CRISPR based innovative diagnostics, state-of-the-art medical devices as well as integrated ‘connected care’ solutions for rural and urban consumers. Our vision is to be a trusted, long-term partner and help shape the evolution of healthcare towards more inclusive and integrated patient-centric solutions that are delivered to consumers using the innovative hybrid ‘Bridgital’ model. By investing in robust partnerships and collaborative frameworks with global industry leaders and research organizations, Tata MD will help build world-class science and technical capabilities as well as drive use of digital technologies to ensure “connected care” for patients. As a company launched during the 2020 pandemic, one defining priority for Tata MD was to develop, launch and scale the availability of affordable diagnostics to treat COVID-19. Our first product is the world’s first commercially available CRISPR Cas-9 based COVID-19 test. It is powered by FELUDA from CSIR-IGIB, a leading Indian biosciences research institute, and will be the new standard for COVID-19 diagnostics. In the future, Tata MD CHECK diagnostics will be extended to other diseases and medical applications as a comprehensive diagnostic tool.